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To identify the top brain regions affected by MS-specific atrophy (i.e., atrophy in excess of
normal aging) and to test whether normal aging andMS-specific atrophy increase or decrease in
these regions with age.
Methods
Six hundred fifty subjects (2,790 MRI time points) were analyzed: 520 subjects with relapse-
onset MS from a 5-year prospective cohort with annual standardized 1-mm 3D T1-weighted
images (3DT1s; 2,483 MRIs) and 130 healthy controls with longitudinal 3DT1s (307
MRIs). Rates of change in all FreeSurfer regions (v5.3) and Structural Image Evaluation
Using Normalization of Atrophy (SIENA) were estimated with mixed-effects models.
All FreeSurfer regions were ranked by the MS-specific atrophy slope/standard error ratio
(βMS × time/SEβMS × time). In the top regions, age was added as an effect modifier to test
whether MS-specific atrophy varied by age.
Results
The top-ranked regions were all gray matter structures. For SIENA, normal aging increased
from 0.01%/y at age 30 years to −0.31%/y at age 60 years (−0.11% ± 0.032%/decade, p < 0.01),
whereas MS-specific atrophy decreased from −0.38%/y at age 30 years to −0.12%/y at age 60
years (0.09% ± 0.035%/decade, p = 0.01). Similarly, in the thalamus, normal aging increased
from −0.15%/y at age 30 years to −0.62%/y at age 60 years (−0.16% ± 0.079%/decade, p <
0.05), and MS-specific atrophy decreased from −0.59%/y at age 30 years to −0.05%/y at age 60
years (0.18% ± 0.08%/decade, p < 0.05). In the putamen and caudate, normal aging and MS-
specific atrophy did not vary by age.
Conclusions
For SIENA and thalamic atrophy, the contribution of normal aging increases with age, but does
not change in the putamen and caudate. This may have substantial implications to understand
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The field ofMS has devoted substantial effort to understanding
and quantifying whole-brain and regional gray matter atrophy
using MRI. Although the exact mechanism is unclear, brain
atrophy in MS is thought to represent the net accumulation of
tissue damage over time. Using MRI, numerous cross-
sectional1,2 and longitudinal3,4 studies have demonstrated the
clinical relevance of whole- and regional brain volume loss in
MS. As such, brain volumetrics, particularly whole-brain vol-
ume, are often incorporated into MS clinical trials and clinical
research as an in vivo proxy of neurodegeneration.
Historically, the literature describing brain atrophy in MS has
generally reported the total volume loss in a given structure,
e.g., whole-brain volume decline of −0.7% to −1.0% per
year.1,4 Only recently has the contribution of normal aging
begun to be explored, mainly in the context of developing
“pathologic cutoff” values for whole-brain volume loss to
discriminate patients with MS from healthy controls
(HCs),5,6 with the ultimate goal of incorporating such values
into a definition of “No Evidence of Disease Activity-4”.7
However, a systematic, unbiased analysis that considers all
brain regions to identify which regions undergo the highest
amounts of excess atrophy in MS compared with normal
aging has not been undertaken.
The excess atrophy in MS that is beyond normal aging, or
“MS-specific atrophy,”8 may be of fundamental importance
because only the excess, disease-related atrophy is presumably
modifiable with therapeutic intervention and should represent
the therapeutic target for treatments aimed at slowing tissue
loss in MS. This requires a robust understanding of normal
aging, which is a complex process that varies across
structures.9–11 After normal head and brain growth during
childhood, each brain structure declines with normal aging.
The age at which the decline begins varies widely across
structures, and the trajectory of decline may be linear or
nonlinear depending on the structure.9–11 For example,
whole-brain atrophy follows a nonlinear trajectory that
accelerates significantly with age.6,12 Because the rate and
trajectory of normal aging decline varies across structures, the
amount of MS-specific atrophy should also vary across brain
structures and as patients age.
The objectives of this analysis are to (1) identify the top brain
regions that undergo the largest, least variable amount of MS-
specific atrophy, and (2) test whether the amount of normal
aging (and therefore the amount of MS-specific atrophy)
increases or decreases in the top regions with age.
Methods
Study population
As described previously,8 from January 2005 through De-
cember 2010, all Caucasian patients aged 18–65 years who
fulfilled the 2005 McDonald Criteria13 for clinically isolated
syndrome (CIS) or MS were offered enrollment into a large,
prospective phenotype-genotype biomarker study (the EPIC
study) at the University of California San Francisco (UCSF)
MS Center. More than 500 subjects with CIS/MS were fol-
lowed longitudinally with annual standardized clinical visits
and 3T brain MRIs for up to 5 years. All EPIC participants
with relapse-onset MS14 were included in this analysis.
To increase the HC sample size, 2 HC data sets were pooled
for this analysis. The first was a convenience sample of 89HCs
(155 MRI time points) from UCSF, recruited separately from
the EPIC cohort, but with brain MRIs performed using the
same 3T MRI scanner and protocol as EPIC. In addition, the
publicly available Alzheimer’s Disease Neuroimaging Initia-
tive database (ADNI; ida.loni.usc.edu) was queried to select
ADNI HCs who had (1) a 3T 3D T1-weighted volumetric
sequence, (2) longitudinal data (≥3 time points), and (3) age
55–70 years. This yielded an additional 41 HCs (152 MRI
time points), for a total of 130 HCs and 307 MRI time points.
Standard protocol approvals, registrations, and
patient consents
Both the EPIC study protocol and the UCSF HC study
protocol were approved by the Committee on Human Re-
search at UCSF, and informed consent was obtained from all
participants. MRIs from ADNI (ClinicalTrials.gov identifier:
NCT00106899) are publicly available.
MRI acquisition
All brain MRI scans from UCSF were acquired using an
8-channel phased array coil in reception and a body coil in
transmission on a 3T GE Excite scanner that did not undergo
hardware upgrades during the 5-year study period. A 3D, T1-
weighted, 1 mm-isotropic, volumetric, inversion recovery
spoiled gradient echo (3DT1) sequence (1 × 1 × 1 mm3, 180
slices) was acquired at each time point (Echo Time/
Repetition Time/Inversion Time = 2/7/400 milliseconds,
flip angle = 15°, 256 × 256 × 180matrix, 240 × 240 × 180 mm3
field of view, number of excitations = 1).
ADNI (adni-info.org) is a multicenter, multinational, NIH-
funded cohort study focused on identifying and validating
biomarkers in Alzheimer disease. All ADNI subjects are
Glossary
ADNI = Alzheimer’s Disease Neuroimaging Initiative database; CIS = clinically isolated syndrome; DMT = disease-modifying
therapy; DTI = diffusion tensor imaging; HC = healthy control; PBVC = percentage whole-brain volume change; RRMS =
relapsing-remittingMS; SIENA = Structural Image Evaluation Using Normalization of Atrophy; SPMS = secondary progressive
MS; UCSF = University of California San Francisco.
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scanned using a standardized brain MRI protocol at 3T after
harmonization and optimization of pulse sequences across
centers using a phantom. Per ADNI requirements, MRI
scanners must be GE, Siemens, or Phillips systems with a 32-
channel coil, and subjects scanned longitudinally at a given
site are required to go back to the same scanner, which is an
accepted research practice to reduce measurement variability
in longitudinal MRI studies.15 At each time point, a 3DT1 is
acquired in sagittal plane with 1 × 1 × 1.2 mm voxel size. Each
scan is reviewed to ensure that the specifications of the ADNI
protocol are met, and a single phantom scan is obtained each
day that an ADNI participant is scanned. Detailed ADNI
procedures and protocols are available online (ida.loni.
usc.edu).
MRI postprocessing
All 3DT1s were processed using our custom in-house pipe-
line, which has been described elsewhere8 and uses Free-
Surfer’s longitudinal processing stream16 (v5.3; surfer.nmr.
mgh.harvard.edu/fswiki/LongitudinalProcessing), lesion
inpainting,17 and manual edits as needed. We extracted final
output from all available 119 brain regions labeled by Free-
Surfer, including subcortical, CSF, ventricular, white matter,
and whole-brain volumes, and cortical thickness measure-
ments. In addition, annual percentage whole-brain volume
change (PBVC) was calculated from 3DT1s using Structural
Image Evaluation UsingNormalization of Atrophy18 (SIENA;
fsl.fmrib.ox.ac.uk/fsl/fslwiki/SIENA).
Statistical analysis
Estimating change over time in each brain region
All statistical analyses were performed in SAS (v9.4). α =
0.05 was used for all hypothesis testing. Paired left and right
volumes were summed, and left and right gyral thickness
measurements were averaged, yielding 83 total FreeSurfer
regions for analysis. Regional volumes were standardized to
percent of intracranial volume. For each brain region, in-
cluding PBVC from SIENA, percent change from the initial
scan was calculated at each time point. The change per year
(atrophy slope) in each brain region was estimated in a lin-
ear mixed-effects model19 as follows:Yij = β00 + β10ðTimeÞij +
β01MS + β11ðMSÞpðTimeÞij + b0j + b1jðTimeÞij + εij20. Thismodel
includes fixed effects for on-study time (in years; β10ðTimeÞij),
case-control status (binary; β01MS), the interaction between
disease status and time (β11ðMSÞpðTimeÞij), which estimates
the additional brain atrophy in MS beyond normal aging
(i.e., MS-specific atrophy), and random effects for intercept and
slope (b0j and b1jðTimeÞij, respectively). Assumptions of the
statistical models were checked via residual plots to examine
the model integrity, normality of residuals, and constant vari-
ance, as well as Cook influence plot to detect potential outliers
with a strong influence on model estimates.
Ranking brain regions
From the linear mixed-effects model in each region, we
extracted the parameter estimate and standard error for
the interaction term β11ðMSÞpðTimeÞij, created a ratioβ11ðMSÞpðTimeÞij
SE½β11ðMSÞpðTimeÞij, and ranked all 83 FreeSurfer regions
according to this ratio. This ratio identifies regions that un-
dergo the highest amount of MS-specific atrophy over time
with the least variability in the estimated change (i.e., the
lowest standard error). Brain regions were ranked in un-
adjusted models, after adjusting for age, and after adjusting for
both age and sex. Age and sex adjustments were performed by
adding age + agepðTimeÞij and sex + sexpðTimeÞij to the model
as fixed effects.
Effect of age on normal aging and MS-specific atrophy
The effect of age at study entry on normal aging and MS-
specific atrophy was explored in the top-ranked FreeSurfer
regions and PBVC from SIENA. To test whether normal
aging and MS-specific atrophy change with age, age was
modeled as an effect modifier in the relationship betweenMS-
specific atrophy and time by adding a 3-way interaction term
plus additional marginal termsage + agepMS + agepðTimeÞij +
agepMSpðTimeÞijÞ to the model listed above. Using the full
model, atrophy slopes for subjects with MS (total atrophy in
MS), HCs (normal aging), and the slope difference between
MS andHCs (MS-specific atrophy) were estimated at ages 30,
40, 50, and 60 years. These ages were chosen a priori to
represent the age range of the subjects withMS in our data set.
MRI scanner as a potential confounder
Because our data set was assembled frommultiple sources, we
tested for potential confounding by testing the interaction
between MRI scanner manufacturer/model and atrophy
slope ði:e: scannerpðTimeÞijÞ. Visual inspection was used to
compare the ranking of brain regions and the point estimate of
atrophy slopes at different age categories before and after
adding scannerpðTimeÞij to the model.
Data availability
Two of the 3 data sets used in this analysis (the EPICMS data
set and the UCSF HC data set) are not sharable publicly. The
acquisition of the brain MRI images in the EPIC MS data set
was funded by investigator-initiated studies sponsored by
pharmaceutical companies. The third data set is publicly
available via the ADNI at ida.loni.usc.edu.
Results
Subject characteristics
Table 1 provides characteristics of the subjects included in this
analysis. Six hundred fifty subjects and 2,790 MRI time points
were analyzed, including 520 subjects with MS (2,483 MRI
time points) and 130 HCs (307 MRI time points). Of the 90
subjects who were classified as CIS at study entry, 47 (52.2%)
were reclassified as relapsing-remitting MS (RRMS) or sec-
ondary progressive MS (SPMS) by their treating physician
during the study period. Of the 392 subjects who were clas-
sified as RRMS at study entry, 21 (5.4%) were reclassified as
SPMS by their treating physician while on study. Four hun-
dred four subjects (77.7% of the cohort) were exposed to
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disease-modifying therapy (DMT), the vast majority of which
were injectable DMTs given the study period (2005–2010).
Ranking of brain regions
The top 5 FreeSurfer regions ranked by the slope/standard
error ratio are given in table 2. Putamen volume, subcortical
gray matter volume, caudate volume, cuneus gyrus thickness,
and thalamic volume were consistently ranked as the top 5
regions across all mixed-effects models, including the un-
adjusted model, after adjusting for age, and after adjusting for
age and sex. Examination of residual plots showed a normal
distribution of residuals and did not indicate any deviations
Table 1 Subject demographics and characteristics
Variable Subjects with MS (n = 520)a HCs (n = 130)a
Age at study entry, y 42.7 ± 9.8 47.9 ± 15.1
Age quartiles
18–35 129 (24.7) 34 (26.4)
36–43 143 (27.6) 21 (16.3)
44–52 142 (27.4) 22 (17.1)
53–69 106 (20.4) 52 (40.3)
Sex
Female 365 (70.2) 83 (63.8)
Male 155 (29.8) 47 (36.2)




Clinical disease duration at study entry, y 9.2 ± 8.6 N/A
Mean EDSS score at study entry 1.8 ± 1.5 N/A
Cumulative DMT exposureb
None 116 (22.3)
≤1 y 33 (6.3)
1–3 y 77 (14.8)
3–5 y 107 (20.6)
>5 y 187 (36.0)
Mean follow-up time, y 4.1 ± 1.6 1.4 ± 1.5
Total MRI time points analyzed 2,483 307
No. of MRI time points
Subjects with 1 MRI 18 49
Subjects with 2 MRIs 47 25
Subjects with 3 MRIs 50 24
Subjects with 4 MRIs 49 24
Subjects with 5 MRIs 111 8
Subjects with 6 MRIs 245 —
Abbreviations: CIS = clinically isolated syndrome; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; HC = healthy control; RRMS =
relapsing-remitting MS; SPMS = secondary progressive MS.
a Mean ± SD for continuous variables, N (%) for categorical variables.
b Cumulative DMT exposure includes all DMT exposure that occurred prestudy and/or on study for each subject (i.e., throughout their lifetime).
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from a linear form, with relatively constant variance across the
fitted range. The Cook influence plot did not show any obser-
vations with Cook distance >1 to indicate an influential outlier.
Effect of age on MS-specific atrophy
The contributions of MS and normal aging to total atrophy in
the putamen, caudate, thalamus, and whole-brain volume
(PBVC from SIENA) at each decade from age 30 to 60 years
are displayed in the figure, with corresponding values in table
3. “Subcortical gray matter volume” in FreeSurfer includes the
thalamus, caudate, hippocampus, amygdala, nucleus accumbens,
ventral diencephalon, and substantia nigra (surfer.nmr.mgh.
harvard.edu/fswiki/MorphometryStats). Because our aimwas to
analyze the effect of age onMS-specific atrophy in separate brain
regions, subcortical gray matter volume was not retained for
further analysis. Cuneus gyral thickness was also not retained
because, unlike the deep gray matter nuclei, which are known to
be affected by MS,21,22 there is a paucity of previous data sug-
gesting specific involvement of the cuneus gyrus.
As shown in figure, A and table 3, the total whole-brain at-
rophy slope (change/y) in subjects with MS from SIENA was
Table 2 Top 5 brain regions ranked by slope/standard error ratio*
FreeSurfer region Unadjusted Age adjustedb Age and sex adjusted
Putamen volume −5.05 −4.74 −4.68
Subcortical gray matter volume −4.11 −3.44 −3.44
Caudate volume −4.13 −3.33 −3.4
Cuneus gyrus thickness −3.0 −2.64 −2.64
Thalamic volume −1.67 −1.67 −1.75
a Slope/standard error ratio is as follows:
β11ðMSÞpðTimeÞij
SE½β11ðMSÞpðTimeÞij . The resulting values are unitless.b Adjustment was made by adding both the marginal effect and the interaction with time, e.g., age + age × time.
Table 3 MS-specific and normal aging atrophy rates by region and decade
Brain region Age 30 y Age 40 y Age 50 y Age 60 y p Value
SIENA
Total atrophy (%/y) −0.37 ± 0.02 −0.39 ± 0.01 −0.41 ± 0.02 −0.43 ± 0.03
MS-specific atrophy −0.38 ± 0.09 −0.29 ± 0.06 −0.21 ± 0.05 −0.12 ± 0.06 0.01
Normal aging 0.01 ± 0.09 −0.10 ± 0.06 −0.21 ± 0.05 −0.31 ± 0.05 <0.01
Thalamus
Total atrophy (%/y) −0.74 ± 0.05 −0.71 ± 0.03 −0.69 ± 0.04 −0.67 ± 0.07
MS-specific atrophy −0.59 ± 0.22 −0.41 ± 0.15 −0.23 ± 0.12 −0.05 ± 0.15 <0.05
Normal aging −0.15 ± 0.21 −0.31 ± 0.15 −0.46 ± 0.12 −0.62 ± 0.13 <0.05
Caudate
Total atrophy (%/y) −1.31 ± 0.07 −1.19 ± 0.04 −1.07 ± 0.05 −0.96 ± 0.08
MS-specific atrophy −0.67 ± 0.26 −0.59 ± 0.19 −0.52 ± 0.15 −0.44 ± 0.18 0.48
Normal aging −0.64 ± 0.26 −0.60 ± 0.18 −0.56 ± 0.14 −0.51 ± 0.16 0.67
Putamen
Total atrophy (%/y) −1.53 ± 0.08 −1.48 ± 0.05 −1.42 ± 0.06 −1.37 ± 0.10
MS-specific atrophy −1.05 ± 0.34 −0.99 ± 0.24 −0.93 ± 0.19 −0.87 ± 0.24 0.66
Normal aging −0.49 ± 0.33 −0.49 ± 0.23 −0.50 ± 0.18 −0.50 ± 0.22 0.97
Abbreviations: HC = healthy control; SIENA = Structural Image Evaluation using Normalization of Atrophy.
Point estimates ± standard error for atrophy rates (percent change per year) in the top brain regions at ages 30, 40, 50, and 60 y for the total rate of atrophy
observed in patientswithMS (“total atrophy”), the rate of atrophy observed inHCs (i.e., normal aging), and the rate ofMS-specific atrophy (slope forMS—slope
for HC), estimated with linear mixed-effects models in each region. The p value given refers to the test of difference in normal aging and MS-specific atrophy
rates between consecutive decades, with the null hypothesis that the difference between consecutive decades equals zero.
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approximately −0.4% per year, consistent across decades.
However, the whole-brain atrophy slopes for MS-specific at-
rophy and normal aging changed significantly with age. The
rate of MS-specific whole-brain atrophy decreased from
−0.38% per year at age 30 years to −0.12% per year at age 60
years, a change of 0.09% ± 0.035% per decade (p = 0.01),
whereas the normal aging atrophy slope increased from 0.01%
per year at age 30 years to −0.31% per year at age 60 years,
a change of −0.11% ± 0.032% per decade (p < 0.01). A similar
pattern was observed in the thalamus (figure, B and table 3).
In the thalamus, the total rate of atrophy in subjects with MS
was approximately −0.7% per year, consistent across decades.
However, the rate of normal aging atrophy accelerated from
−0.15% per year at age 30 years to −0.62% per year at age 60
years (−0.16% ± 0.079% per decade, p < 0.05), whereas the
rate of MS-specific atrophy decreased from −0.59% per year at
age 30 years to −0.05% per year at age 60 years (0.18% ±
0.08% per decade, p < 0.05).
A very different pattern was observed in the putamen and
caudate (figure, C and D and table 3). In these regions, the
contributions of normal aging and MS-specific atrophy did
Figure Contribution of normal aging to total atrophy in MS by decade
Stacked histograms showing the trend of brain atrophy slopes by age in HCs (green) andMS-specific atrophy (blue). The total rate of atrophy in patients with
MS is represented by the total height of each histogram bar (combining colors). For SIENA (A) and thalamus (B), the contribution of MS-specific atrophy and
normal aging to the total atrophy slope changed significantly across decades, whereas normal aging was stable across decades in the caudate (C) and
putamen (D). HC = healthy control; SIENA = structural image evaluation using normalization of atrophy.
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not vary significantly with age. In the caudate, the normal
aging and MS-specific atrophy slopes were stable across
decades, with nonsignificant changes of 0.04 ± 0.10 (p = 0.67)
and 0.07 ± 0.11 (p = 0.48) per decade, respectively. Similarly,
in the putamen, the rate of normal aging (−0.01% ± 0.13%, p =
0.97) and MS-specific atrophy (0.06% ± 0.14%, p = 0.66) did
not change significantly across decades.
Type of MRI scanner as a potential confounder
None of the interaction tests between the type of MRI
scanner and the atrophy slope ðscannerpðTimeÞij   Þ were sta-
tistically significant. The rankings and parameter estimates did
not change after adding scannerpðTimeÞij to the model, sug-
gesting that scanner manufacturer/model did not confound
our findings.
Discussion
We used an agnostic approach to identify the top brain
regions with the highest, least variable amount of yearly MS-
specific atrophy in a large, 5-year, prospective cohort of
subjects with MS and estimated the contribution of normal
aging to atrophy measurements in the top-ranked regions at
each decade from ages 30 to 60 years. Out of every region in
the human brain that is labeled by FreeSurfer, all the top-
ranked regions were gray matter structures, including 3 deep
gray nuclei and 1 cortical gyrus. This is consistent with
previous histopathologic and MRI studies suggesting in-
volvement of deep and cortical gray matter in the MS disease
process21–23 and underscores the importance of gray matter
in MS.
More importantly, our findings indicate that for whole-brain
(SIENA) and thalamic volume, the contribution of normal
aging to total atrophy may increase significantly as the MS
population ages. In these regions, most of the atrophy we
observed at age 30 years was clearly in excess of normal aging
and presumably disease related, whereas by age 60 years, the
rate of normal aging had accelerated such that there was little
excess atrophy attributable to MS. In the caudate and puta-
men, on the other hand, we observed a stable contribution of
normal aging at each decade. In the case of whole-brain at-
rophy, our observed acceleration of normal aging is consistent
with existing literature12 and has been observed in other
studies using SIENA.5,6 Although normal aging in subcortical
structures is perhaps less well characterized, a similar pattern
of behavior could plausibly occur. Some subcortical structures
such as the amygdala, caudate, and thalamus have been shown
to follow a linear decline over the lifespan in normal aging,
whereas others such as the hippocampus may follow a qua-
dratic (i.e., nonlinear) trajectory.11 Most of the studies
modeling atrophy in subcortical structures in normal aging
have used cross-sectional data sets composed of 1.5T MRIs
and relatively simplified statistical methods (i.e., linear or
quadratic age terms) to estimate the effect of age.9–11 Our data
sets were composed of longitudinal 3T MRIs, and we used
a more complex modeling strategy, making direct compar-
isons with published literature somewhat difficult.
We found that different brain regions behaved differently with
respect to MS-specific atrophy vs normal aging. This suggests
that tissue loss in MS may occur for reasons that are distinct
across brain regions. Axonal transection within white matter
demyelinating lesions24 can lead to upstream or downstream
neurodegeneration, which likely contributes to whole-brain
and thalamic atrophy in MS.25,26 This may be a particularly
important mechanism of thalamic atrophy, which is an area of
early neurodegeneration in MS.26–29 A strong preponderance
for MS lesions to form in thalamocortical white matter and
a probable mechanistic link between thalamocortical white
matter lesions and thalamic atrophy has been demonstrated
using diffusion tensor imaging (DTI) tractography in subjects
with CIS.26 We hypothesize that the downstream effects of
white matter lesions may explain the predominantly disease-
related atrophy we observed at younger ages in whole brain
and thalamus, whereas regions with fewer incoming long
white matter tracts such as the caudate and putamen would
presumably be less influenced by demyelinating injury. In-
deed, in the caudate and putamen, the contributions of nor-
mal aging and MS-specific atrophy remained stable with age.
Future work could test this hypothesis using a similar DTI
tractography approach26 to delineate incoming and outgoing
tracts in the putamen and caudate and to estimate the effect
(or lack thereof) of tract-specific white matter lesions on the
volume of each structure. If we have indeed identified gray
matter regions that are undergoing a high amount of excess
MS-specific tissue loss that is relatively independent of white
matter lesions, this may open a rich avenue for further ex-
ploration that could provide fundamental insights into tissue
loss in MS. These regions could be used to study the con-
tribution of other aspects of MS pathology to gray matter
atrophy, such as intrinsic gray matter demyelinating
lesions,21,22 iron deposition,22 microglial activation,30 mito-
chondrial dysfunction,31 and glutamate excitotoxicity,32
which could lead to a more comprehensive understanding of
gray matter atrophy in MS.
Our findings may have implications for clinical trial design and
interpretation. If we presume that only the MS-specific atro-
phy is amenable to therapeutic intervention (i.e., that DMTs
will not slow normal aging), our data suggest that the most
appropriate brain region for a phase II primary end point, as
well as the effect size that can reasonably be achieved and the
sample size needed to demonstrate efficacy, may differ
according to the patient population being studied (early vs
late MS, older vs younger patients, etc.). More generally,
a better understanding of the time and/or age where MS-
specific atrophy is most prominent may help elucidate the
“therapeutic opportunity” for current and future DMTs. Our
findings could at least partly explain the suggestion in our
literature that some DMTs aimed at slowing disease pro-
gressionmay not work as well in older patient populations,33–35
perhaps because normal aging is more prominent and there is
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less “therapeutic opportunity” present. Finally, our data sup-
port the notion that any “pathologic cutoff” value used to
discriminate patients with MS from HCs must be adjusted for
age, which has also been suggested by the work of others.5,6
Our findings should not suggest that patients with MS at age
60 years are no longer undergoing pathologic disease-related
whole-brain or thalamic atrophy. In fact, the total rate of
whole-brain and thalamic atrophy in our subjects was con-
sistent throughout the age range at −0.4% and −0.7% per year,
respectively. Rather, our data suggest that normal aging
accelerates with age in these regions, which mathematically
decreases the excess atrophy because normal aging and MS-
specific atrophy were estimated in the same statistical model.
Whether whole-brain or regional gray matter atrophy accel-
erates throughout the MS disease duration has been unclear,
with some studies suggesting an acceleration of gray matter
atrophy in SPMS compared with RRMS36,37 and other, more
recent work finding no difference in deep gray matter atrophy
rates across MS subtypes.8,38 We examined the effects of age
rather than clinical subtype; although age and clinical subtype
are typically correlated, these should not be conflated. Finally,
our findings describe a group-level difference between sub-
jects with MS and HCs. Translating these findings to the
individual level is an area of high interest that will require the
development of methods to create an MS-specific atrophy
biomarker for an individual; exploration of the clinical rele-
vance of such a biomarker is likely to be informative. How-
ever, presently, it is premature to apply the current findings at
the individual level.
Our approach that focuses on excess, disease-specific atrophy
could be applied to other imaging metrics in MS and to other
neurodegenerative diseases such as Alzheimer disease, Par-
kinson disease, and Huntington disease, in which a similar
conceptual model should apply. If one could estimate and
adjust for the impact of normal aging, disease-specific atrophy
measurements could allow for comparison across neurode-
generative diseases, which could uncover biologic, environ-
mental, genetic, and phenotypic similarities (and differences)
between diseases that could ultimately further our un-
derstanding of neurodegeneration in general. Furthermore, an
impact of medical and psychiatric comorbidities on brain
atrophy has been demonstrated in both MS39–41 and non-
MS42–45 subjects. This emerging area deserves further ex-
ploration. Because our data sets did not contain information
on comorbidities, we were not able to examine their influence
on our results. However, all brain regions in a given patient
would have been exposed to the samemilieu of comorbidities;
therefore, it is unlikely that the impact of comorbidities
explains our observation of differing behavior between deep
gray matter regions. Similarly, the presence or absence of
DMT is unlikely to explain our findings, unless one
hypothesizes a differential impact of DMT on one deep gray
matter structure vs another. Estimating the impact of
comorbidities and DMTs on regional brain atrophy inMSwill
be an area of focus in future studies.
Strengths of this work include the large sample size, longitu-
dinal study design, careful acquisition and postprocessing of
MRI data, and the unbiased selection strategy of the top
regions of interest, which incorporates normal aging. Our
approach of separating normal aging from disease-related
atrophy is novel in brain atrophy analyses in the current MS
literature and has several implications for MS and other
neurodegenerative diseases that could be highly impactful.
Limitations include a shorter mean follow-up time in HCs
compared with subjects with MS and a relatively small HC
sample size. HC MRI data, particularly longitudinal data, are
rare in clinical research; efforts to assemble larger HC data sets
are ongoing. However, to achieve the meaningful sample sizes
that will be needed to fully understand normal aging will
invariably require leveraging and combining multiple existing
HC data sets composed of subjects scanned on different
scanners, as we did in this analysis. Although this may initially
prompt concern for increasing measurement variability, each
HC subject in this analysis was required to be scanned lon-
gitudinally on the same MRI scanner throughout their study
period, which reduces variability.15 Moreover, we modeled
the brain volume changes in this analysis as a percent change
from baseline, which obviates the concern regarding hetero-
geneity across MRI scanners. Finally, by definition, linear
mixed-effects models assume a linear decline in the outcome
variable (brain volume) over time. Additional work with
larger MRI data sets over a much larger age range is underway
and will use advanced, nonlinear modeling strategies to fur-
ther disentangle the contribution of normal aging from the
pathologic atrophy observed in MS.
In summary, our findings indicate that the contribution of
normal aging may increase with age and the rate of MS-
specific atrophy may decrease with age in thalamic and whole-
brain atrophy measurements in MS, whereas normal aging
and MS-specific atrophy do not change with age in the
putamen and caudate. This work emphasizes the need to
understand each brain region separately in MS and has many
potential implications for MS and perhaps for other neuro-
degenerative diseases. This could inform future work that
furthers our fundamental understanding of brain atrophy in
MS, including whether there are different causes of regional
tissue loss and how to interpret the effect of disease-modifying
therapies with age.
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